SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its strong Q4 earnings, profitability, and new share buyback authorization have ironically led to a significant stock decline, sparking widespread frustration among investors. The community is fiercely debating whether ongoing stock-based compensation and dilution are overshadowing the company's growth in subscriptions and long-term potential in AI/AR smartglasses.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as the FDA's swift action against compounded GLP-1s from Hims & Hers validates legitimate drug development, amplifying speculation that Viking's "best-in-class" VK2735 is a critical acquisition for companies like Novo Nordisk, which face intense competition from Eli Lilly in the booming obesity market.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

Tradr's recently launched 2X leveraged ETF, $CRMX, tracking Critical Metals ($CRML) and its rare earth projects, is actively discussed as traders debate its actual leverage performance and monitor for a potential breakout from quiet accumulation on increased volume. Many are closely watching its tight consolidation and small float dynamics for an upward move.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its recent earnings report, which showed a revenue miss attributed to contract transitions and a government shutdown, despite an EPS beat and a growing backlog. The community is actively debating whether the post-earnings stock dip is an over-reaction, with many long-term investors highlighting the company's crucial role in nuclear energy, space systems, and defense contracts as a strong foundation for future growth.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE CRYPTO is trending for its notable resilience and positive price action in a challenging market, driven by a dedicated community actively accumulating and promoting its narrative as the "third frog" and literal representation of Pepe by creator Matt Furie. Despite some labeling it a scam, proponents are confident in its organic growth and potential as a prime frog meta beta play.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following its strong Q3 fiscal year 2026 earnings report, which surpassed expectations across key metrics and included the authorization of a $1 billion share repurchase program. This positive financial performance and commitment to shareholder returns are fueling optimistic discussions among the community, despite some recent analyst target adjustments.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending following its strategic pivot to an AI-enabled fintech platform, CapForce, with the community actively discussing an anticipated NASDAQ relisting and the potential for explosive price movements given its extremely low float. Recent compliance filings and strategic acquisitions are fueling optimism for its new direction.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund (UUP) is trending as the US dollar faces pressure from widespread expectations of future Fed rate cuts and a broader "risk-on" market sentiment favoring equities and commodities. The community is discussing a potential dollar breakdown, with some linking weakness to de-dollarization concerns and a surge in precious metals like gold and silver.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum (LITE) is trending as a critical optical component supplier for the booming AI data center infrastructure, fueled by its collaboration on Nvidia's power-efficient silicon photonics and a recent earnings beat with strong guidance. The community is actively discussing its significant growth potential as an AI networking backbone versus concerns about its rapid valuation surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$207B Market Shift: The Race for Fast Track Approval in Oncology

$207B Market Shift: The Race for Fast Track Approval in Oncology $207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire VANCOUVER, BC, Feb. 5, 2026 Issued on behalf of...

<ul class="summary-bullets"><li>The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy.&nbsp;</li><li>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally.</li><li>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer.</li></ul><p>Shares of Oncolytics Biotech Inc. (ONCY) rallied 8% at the time of writing ON Wednesday after the company announced that the U.S. Food and Drug Administration has granted a fast track designation to its cancer drug pelareorep in combination with other drugs.</p><p>The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer for whom few effective treatment options exist.</p><h2 class="st-heading-2">Why The Designation?</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/04/3232074/0/en/Oncolytics-Biotech-Receives-FDA-Fast-Track-Designation-for-Pelareorep-in-2L-KRAS-Mutant-MSS-Metastatic-Colorectal-Cancer.html">said</a> that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy compared to approximately 10% ORR with standard-of-care in the particular patient population.</p><p>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally, with an annual total addressable market of approximately $3-5 billion for the subgroup it targets.</p><h2 class="st-heading-2">Plans Ahead</h2><p>The company now intends to initiate a controlled clinical study in the subgroup comparing standard-of-care therapy alone versus standard-of-care plus pelareorep.</p><p>The first clinical site, it noted, is expected to be activated in March, with up to 10 additional sites expected to open shortly thereafter. Interim data from the study are expected by year-end, it added.</p><h2 class="st-heading-2">Perks Of The Designation</h2><p>The Fast Track Designation enables more frequent meetings and communication with the regulator to ensure alignment on development plans and the collection of clinical data needed to support approval. Programs with Fast Track Designation may also be eligible for accelerated approval and priority review if certain criteria are met.</p><p>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer. The company is also studying the drug in metastatic breast cancer.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ONCY stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user highlighted high price targets on the stock.</p><p><stembedurl>https://www.stocktwits.com/sk7777777/message/643949165</stembedurl></p><p>According to data from Koyfin, of the seven analysts covering the stock, six have a ‘buy’ or higher rating on the shares of the company while one rates it ‘hold’.</p><p>The stock has an average price target of $5.49, representing a potential upside of over 400% from current trading levels.</p><p><a href="https://stocktwits.com/symbol/ONCY">ONCY stock</a> has gained 32% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ionq-stock-tumbles-as-wolfpack-reveals-short-position/cZbj44zR4NP">IONQ Stock Tumbles 10% As Wolfpack Reveals Short Position</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug

The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer. 

Equity

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire VANCOUVER, BC, Jan. 27, 2026...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Purchases 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger bought 100,000 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was bought at an...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Acquires 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger purchased 100,000 shares of the company's stock in a transaction on Friday, January 16th. The stock was acquired at an...

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire VANCOUVER, BC, Jan...

Smart Oncology: 5 Stocks Chasing the $317B Prize

Smart Oncology: 5 Stocks Chasing the $317B Prize Smart Oncology: 5 Stocks Chasing the $317B Prize PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Oncolytics Biotech Inc...

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech, Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.06	--	--	N/A
Q3 '25	-$0.06	-$0.10	-61.53%	MISSED
Q2 '25	-$0.07	-$0.05	30.19%	BEAT
Q1 '25	-$0.07	-$0.06	17.84%	BEAT
Q4 '24	-$0.09	-$0.07	19.87%	BEAT

ONCY
Oncolytics Biotech, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ONCY News

ONCYOncolytics Biotech, Inc.